Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHC014748M in Relapsed/Refractory Indolent B-Cell Hematologic Malignancies
NCT03588598Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of shc014748m in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 1 more, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 1 month, Time to Peak Plasma Concentration at 1 month and 3 more. Status: unknown.
02
Drugs
shc014748m
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03588598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588598.